Green Cross Labcell said Thursday that it has completed its patent registration related to the cultivation of natural killer cells in the U.S.
The U.S. is the third country to approve the company’s patent after the EU and Japan. The patents acquired by the company relates to natural killer cell mass production and freezing technology owned by the company.
Natural killer cells are innate immune cells that immediately destroy cancer cells or abnormal cells in human body. However, the cells are difficult to cultivate and have a short activation period, which makes mass volume production and long-term stability vital for the treatment’s commercialization.
“Our company’s culture method is optimal for producing highly active and pure natural killer cells, which are used to treat tumors and infectious diseases,” the company said in a statement. “The patent also includes a technology capable of storing mass-produced natural killer cells for a long period.”
The company has recently entered phase 2 clinical trial for MG4101, a liver cancer treatment using natural killer cells. The substance is currently the leading natural killer cell treatment preparing for commercialization.
“Green Cross Labcell 녹십자랩셀 has become the world leader in the field by steadily acquiring the unique technologies required for the development of natural killer cell therapy,” said Hwang Yu-kyung 황유경, director of Green Cross Labcell’s cell therapy research center.
Green Cross Labcell plans to accelerate the development and commercialize natural killer cell treatment continuously.
<© Korea Biomedical Review, All rights reserved.>